乙型肝炎病毒基因突变检测分析  

Analysis for Detection Results of YMDD Mutants in HBV and Its Clinical Values

作　　者：黄杰[1] 邹长敏[1] 李健红[1] 曾屏[1] 郭平[1] 

机构地区：[1]成都市第三人民医院,四川成都610031

出　　处：《成都医药》2004年第3期138-139,共2页

摘　　要：目的 :检测乙型肝炎患者HBV基因突变 ,为临床治疗乙型肝炎联合用药或单一用药提供实验室依据。方法 :采用RocheLightCyclerTM荧光PCR定量分析仪 ,应用FQ -PCR技术进行乙肝病毒基因突变 (YMDD)及HBV -DNA的检测。结果 :经半年以上的临床治疗观察 ,拉米夫定加胸腺肽联合用药组 2 0例乙肝患者未检测出YMDD变异株 ,用药后HBV -DNA和ALT检测指标分别随治疗的进度拷贝数降低和恢复正常 ;而单一服用拉米夫定药物治疗组 37例乙肝患者 ,检测出发生YMDD变异有 8例 ,阳性率2 2 % ,其中YIDD型 6例 ,YVDD型 2例 ,HBV -DNA和ALT检测结果的反跳分别占 5 .4 %和 8.1%。结论 :乙型肝炎病毒耐药基因突变的检测有助于临床有效治疗。Objective:To detect the gene mutants in HBV , provide the evidence for the treatment of HBV.Methods:To use the fluorescent PCR quantitative analyzer ,Roche LightCycler TM, and FQ-PCR technology to detect the YMDD mutants of HBV and HBV-DNA.Results: After clinical treatment more than half year, there are no YMDD mutants in 20 HBV patients treated by the lamivudine combined with thymosin synchronously, the quantities of copy of HBV-DNA and ALT decreased even to normal during the treatment. But there are 8 cases YMDD mutants including 6 cases YIDD mutants and 2 cases YVDD mutants in 37 HBV patients treated only by the lamivudine. The positive rate is 22% and the rebound rate is 5.4% and 8.1% respectively for HBV-DNA and ALT.Conclusion:The detection of drug-resistance mutants in HBV can help the clinical treatment effectively.

关 键 词：乙型肝炎病毒 基因突变 检测 耐药基因 

分 类 号：R373.21[医药卫生—病原生物学] R394[医药卫生—基础医学]